1-6 of 6
Marc Michel IV
Close
Sort by
Journal Articles

The Use Of Rituximab For Preventing Delayed Haemolytic Transfusion Reaction In Highly Immunized Patients With Sickle Cell Disease

France Noizat-Pirenne, MD-PhD, Marc Michel, IV, Armand Mekontso-Dessap, Constance Guillaud, Keyvan Razazi, Matthieu Mahévas, Sadaf Pakdaman, Frederic Galacteros, MD PhD, Pablo Bartolucci, MD, PhD, Anoosha Habibi, MD
Journal: Blood
Blood (2013) 122 (21): 1162.
https://doi.org/10.1182/blood.V122.21.1162.1162
Published: 2013
Journal Articles

The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients

Mathilde Lamarque, MD, Véronique Leblond, MD, PhD, Bruno R. Varet, MD, Sylvain Choquet, MD, Jean Paul Vernant, MD, Richard Delarue, MD, Bertrand Godeau, MD, Olivier Hermine, MD, PhD, Marc Michel, IV
Journal: Blood
Blood (2013) 122 (21): 2193.
https://doi.org/10.1182/blood.V122.21.2193.2193
Published: 2013
Journal Articles

Safety and Efficacy Of Rituximab In adult’s Immune Thrombocytopenia (ITP) : Results After One-Year Of Follow-Up In 252 Patients From The Prospective French ITP-Ritux Registry

Mehdi Khellaf, Olivier Fain, Louis Terriou, MD, Jean-François Viallard, MD, PhD, Stéphane Cheze, roudot-Thoraval Françoise, Mohamed Hamidou, Borhane Slama, Sylvain Audia, M.D., Ph.D., Nicolas Schleinitz, MD, PhD, Manuel Cliquennois, MD, Guillaume le Guenno, MD, Caroline Bonmati, MD, France Teillet, Olivier Lambotte, MD, PhD, Gwenola Maigne, Lionel Galicier, MD, Arnaud Hot, Francois Lefrere, Daniel Adoue, MD, Dominique Bordessoule, MD, PhD, Xavier Delbrel, Didier Bouscary, MD, Jean-Yves Cahn, MD, Alaa Ghali, Denis Verrot, Alain Delmer, MD, Patrick Jego, Julie Magnant, Anne-Laure Buchdahl, Bruno Royer, MD, Sophie Rosenstingl, Jean-Marc Durand, Philippe Bierling, MD, Marc Michel, IV, Bertrand Godeau, MD
Journal: Blood
Blood (2013) 122 (21): 450.
https://doi.org/10.1182/blood.V122.21.450.450
Published: 2013
Journal Articles

Prolonged Remission After TPO-Receptor Agonist Discontinuation In Adults With Chronic ITP. Results Of a French Observational Study

Matthieu Mahévas, Olivier Fain, Mikael Ebbo, Medhi Khellaf, Nicolas Limal, Nicolas Schleinitz, MD, PhD, Corinne Haioun, MD, PhD, Philippe Bierling, MD, Bertrand Godeau, MD, Marc Michel, IV
Journal: Blood
Blood (2013) 122 (21): 327.
https://doi.org/10.1182/blood.V122.21.327.327
Published: 2013
Journal Articles

Cost Effectiviness of Rituximab Given At Fixed Dose (1000 mg on days 1 and 15) Compared to the Standard Regimen in adult's Immune Thrombocytopenia.

Matthieu Mahévas, Mikael Ebbo, Sylvain Audia, M.D., Ph.D., Bernard Bonnotte, M.D., Ph.D., Nicolas Schleinitz, MD, PhD, Corinne Haioun, MD, PhD, Medhi Khellaf, Bertrand Godeau, MD, Marc Michel IV
Journal: Blood
Blood (2012) 120 (21): 2157.
https://doi.org/10.1182/blood.V120.21.2157.2157
Published: 2012
Journal Articles

Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),

Jeffrey Wasser, MD, Ralph Vincent V. Boccia, MD, Roger M. Lyons, MD, Romeo Mandanas, Ingrid Pabinger, Marc Michel IV, Jean-François Viallard, MD-PhD, Xuena Wang, PhD, Richard Lizambri, MD
Journal: Blood
Blood (2011) 118 (21): 3282.
https://doi.org/10.1182/blood.V118.21.3282.3282
Published: 2011